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Dengue viruses (DENV) cause countless human deaths each year, whilst West Nile virus (WNV)
has re-emerged as an important human pathogen. There are currently no WNV or DENV vaccines
licensed for human use, yet vaccines exist against other flaviviruses. To investigate flavivirus
cross-reactivity, sera from a human cohort with a history of vaccination against tick-borne
encephalitis virus (TBEV), Japanese encephalitis virus (JEV) and yellow fever virus (YFV) were
tested for antibodies by plaque reduction neutralization test. Neutralization of louping ill virus (LIV)
occurred, but no significant neutralization of Murray Valley encephalitis virus was observed. Sera
from some individuals vaccinated against TBEV and JEV neutralized WNV, which was enhanced
by YFV vaccination in some recipients. Similarly, some individuals neutralized DENV-2, but this
was not significantly influenced by YFV vaccination. Antigenic cartography techniques were used
to generate a geometric illustration of the neutralization titres of selected sera against WNV,
TBEV, JEV, LIV, YFV and DENV-2. This demonstrated the individual variation in antibody
responses. Most sera had detectable titres against LIV and some had titres against WNV and
DENV-2. Generally, LIV titres were similar to titres against TBEV, confirming the close antigenic
relationship between TBEV and LIV. JEV was also antigenically closer to TBEV than WNV, using
these sera. The use of sera from individuals vaccinated against multiple pathogens is unique
relative to previous applications of antigenic cartography techniques. It is evident from these data
that notable differences exist between amino acid sequence identity and mapped antigenic
relationships within the family Flaviviridae.
INTRODUCTION
Within the family Flaviviridae, the genus Flavivirus
comprises tick-borne, mosquito-borne and no-known-
vector viruses, and virus species are further placed into
groups with shared antigenic cross-reactivity (Porterfield,
1980). West Nile virus (WNV) belongs to the Japanese
encephalitis virus (JEV) serocomplex along with viruses
including JEV, Murray Valley encephalitis virus (MVEV)
and St. Louis encephalitis virus. Other serocomplexes
include yellow fever virus (YFV), Dengue virus (DENV)
and tick-borne encephalitis virus (TBEV), which contains
three subtypes of TBEV and louping ill virus (LIV)
(Porterfield, 1980; Calisher et al., 1989). This classification
has largely been supported by genomic phylogeny (Gaunt
et al., 2001; Grard et al., 2007).
A number of flaviviruses constitute a significant threat to
global health. DENV infection causes around 21000
human deaths annually, and it is estimated that at least
120 countries have endemic DENV transmission (Thomas
& Endy, 2011), whilst in recent years, WNV has become
more prominent as a zoonotic agent, particularly in North
America where the virus first emerged in 1999 and rapidly
spread across the continent (Nash et al., 2001). WNV
has now emerged in a number of European countries,
particularly around the Mediterranean basin, where
infections in humans, horses and birds have been reported
(Huba ´lek et al., 1999; Murgue et al., 2001; Autorino et al.,
2002; Bakonyi et al., 2006; Krisztalovics et al., 2008; Rizzo
et al., 2009). In particular, a substantial number of human
infections have recently been detected in Greece (Papa
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antibodies to WNV in earlier human and animal
seroprevalence studies. This suggests that WNV had been
circulating previously, and certain conditions had favoured
increased numbers of Culex mosquitoes, which resulted in
human WNV cases. As the European climate continues to
change, this could occur elsewhere in Europe.
There are no licensed vaccines approved for use in humans
against WNV (Kramer et al., 2008) or DENV (Thomas &
Endy, 2011). However, human vaccines are available
against other flaviviruses, including TBEV, JEV and YFV.
Cross-reactivity of sera raised against one flavivirus
recognizing another flavivirus has been well documented
(Calisher et al., 1989). Studies with mAbs have identified
cross-reactive sites on the envelope glycoproteins of
different flavivirus species (Peiris et al., 1982; Takegami
et al., 1982; Kimura-Kuroda & Yasui, 1986; Heinz et al.,
1983; Schlesinger & Brandriss, 1983; Beasley & Barrett,
2002), but relationships within and between serocomplexes
are inconsistent (Calisher et al., 1989). One consequence of
flavivirus cross-reactivity is the occurrence of false-positive
results (Hirota et al., 2010), yet cross-reactivity can lead to
cross-protection. Pre-existing vaccine-induced immunity
to TBEV has been shown to enhance the neutralizing
antibody response following vaccination with an inactiv-
ated JEV vaccine candidate (Schuller et al., 2008), whilst
separate studies in hamsters have demonstrated that prior
inoculation with one flavivirus lead to a reduction in
severity of subsequent challenge with a different flavivirus
(Tesh et al., 2002; Bosco-Lauth et al., 2011).
A panel of sera was obtained from a human cohort
vaccinated against TBEV, JEV and YFV (n528), and the
neutralization profile assessed against a range of flavi-
viruses. Sera were tested by plaque reduction neutralization
test (PRNT), and assessment was made both within, and
between, serocomplex groups. Using antigenic cartography
techniques, a geometric interpretation of the titres of
selected human sera against WNV, TBEV, JEV, LIV, YFV
(two strains) and DENV-2 was made. This analysis is
unique relative to previous uses of antigenic cartography
for influenza, rabies and enterovirus (Smith et al., 2004; de
Jong et al., 2007; Russell et al., 2008; Huang et al., 2009;
Garten et al., 2009; Horton et al., 2010), enabling high
resolution quantitative analysis and visualization of
antigenic relationships of flaviviruses.
RESULTS
Neutralizing antibody response to vaccination
against TBEV, JEV and YFV
All the neutralization results for the sera obtained from
the flavivirus-vaccinated human cohort are provided in
Supplementary Table S1 (available in JGV Online). When
tested by TBEV-specific PRNT, 64% of the samples tested
(n525) achieved a .50% reduction in plaque numbers
(PRNT50) titre of at least 1:10, 36% achieved a PRNT50
titre of at least 1:20 and 16% achieved a PRNT50 titre of at
least 1:40 (Fig. 1a, left panel).
Neutralizing antibody to JEV was observed in 89.3% of the
samples tested (n528) as assessed by JEV-specific PRNT,
where a PRNT50 titre of at least 1:10 was achieved. Indeed,
64.3% of the samples achieved a PRNT50 titre of at least
1:40 (Fig. 1a, left panel).
Neutralizing antibody response against the 17D and Asibi
strains of YFV was determined by YFV-specific PRNT,
where PRNT50 titres of at least 1:20 were achieved by 34.6
and 38.5% of the samples tested (n526) against 17D and
Asibi, respectively (Fig. 1a, right panel).
Effect of gender on neutralizing antibody
response
Gender of participants appeared to have no significant
effect on neutralizing antibody titres (data not shown)
(Student’s t-test: P50.41, 0.06, 0.34, 0.55, 0.37, 0.73 and
0.97 for TBEV, JEV, LIV, WNV, YFV 17D, YFV Asibi and
DENV-2, respectively).
Cross-neutralization of LIV
A majority of individuals were able to neutralize LIV, with
68% of samples demonstrating a PRNT50 titre of at least
1:10 and a further 20% demonstrating a titre of 1:20 or
higher (Fig. 1b, left panel). One individual achieved a titre
of 1:1280.
The Spearman’s rank correlation coefficient (0.674)
between the titres of LIV and TBEV PRNT50 was highly
significant (P,0.001).
Cross-neutralization of MVEV
None of the samples from the cohort demonstrated
detectable levels of neutralization of MVEV by PRNT50
(Supplementary Table S1). However, minimal neutraliza-
tion was observed at a serum dilution of 1:10 for some
participants, but this was not sufficient to give a positive
PRNT50 titre, and was not related to vaccination against
YFV in those individuals (Student’s t-test, P50.622).
Cross-neutralization of DENV-2
Of the samples tested (n526), 38.5% achieved a PRNT50
titre of at least 1:20, with 11.5% achieving a titre of at least
1:40 (Fig. 1b, centre panel). Spearman’s rank correlation
analysis provided no evidence of an association between
titres against DENV-2 and either JEV, YFV 17D or YFV
Asibi (P50.530, 0.346 and 0.117, respectively). Further-
more, the titres from YFV-vaccinated individuals were not
significantly different from individuals who were not
vaccinated against YFV (Kruskall–Wallis test, P50.070),
indicating that any effect of vaccination against YFV on the
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detected using these data.
Cross-neutralization of WNV
Cross-neutralization of WNV by PRNT (achieving a
PRNT50 titre of at least 1:10) was observed in nine
individuals (32.1% of the sample population), where six
individuals (21.4%) recorded a PRNT50 titre of 1:20 or
higher (Fig. 1b, right panel). The Spearman’s rank
correlation coefficient (0.490)betweenPRNT50titresagainst
WNV and YFV Asibi indicate a significant positive
association (P50.017). Similarly, the Spearman’s rank
correlation coefficient (0.386)betweenPRNT50titresagainst
WNV and YFV 17D indicate a positive association that is
just significant (P50.047). Individuals who had been
vaccinated against YFV as well as TBEV and JEV were more
likely to neutralize WNV (achieving a PRNT50 titre of at
least 1:10) than individuals who had only been vaccinated
against TBEV and JEV (Fig. 2). Three individuals were
unable to confirm whether they had received YFV
vaccination. Of the individuals who had been vaccinated
against TBEV and JEV only (n514), only 7.1% were able to
neutralize WNV, achieving a PRNT50 titre of at least 1:10.
In comparison, of the individuals who had received an
additional vaccination against YFV (n511), 54.5% demon-
strated neutralization of WNV, achieving a PRNT50 titre of
at least 1:10. The titres of YFV-vaccinated individuals were
significantly higher than those from unvaccinated indiv-
iduals (Kruskall–Wallis test, P50.002), confirming that
people vaccinated against YFV were more likely to neutralize
WNV than those not vaccinated against YFV. This result
confirmed that vaccination status appeared to influence the
ability to neutralize WNV. From this study, the effect of JEV
vaccination on the ability to neutralize WNV is unclear,
since the majority of individuals were known to have
received the vaccination. The proportion of sera with a JEV
PRNT50 titre of at least 1:10 for the WNV PRNT-negative
Fig. 1. (a) Seroconversion following vaccination against TBEV (n525) and JEV (n528) (left panel), and YFV (n526) (right
panel; strain 17D and strain Asibi). Proportion of sera (% sera) achieving a neutralizing antibody titre of ¢1:10, ¢1:20 or
¢1:40, or no neutralization (Neg), as determined by PRNT50. (b) Cross-neutralization of LIV (n525), WNV (n528) and DENV-
2( n526) (left, centre and right panels, respectively). Proportion of sera (% sera) achieving a neutralizing antibody titre of
¢1:10, ¢1:20 and ¢1:40, or no neutralization, as determined by PRNT50.
Antibody cross-reactivity between flaviviruses
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for the WNV PRNT-positive samples (100%) by Fisher’s
exact test (P50.530), whereas the Spearman’s rank correl-
ation coefficient (0.437) between the titres of the two tests
was significant (P50.021).
Results for all PRNT data from individuals that neutralized
WNV are detailed in Table 1.
Visualization of the neutralization data using
antigenic cartography techniques
Antigenic cartography has provided a novel means of
visualizing and quantifying the relationship between serum
titres and closely related antigens to which they react. The
geometric interpretation of the neutralization titres is
illustrated in Fig. 3, demonstrating the antigenic relation-
ships among TBEV, JEV, LIV, WNV, YFV and DENV-2 as
determined by these sera. The dispersal of the sera on the
map illustrates the differences in each participant’s cross-
neutralization responses. Despite being from volunteers
only vaccinated against TBEV, JEV and in some cases YFV,
most sera had detectable titres against LIV and some had
titres against WNV and DENV-2. In most cases the LIV
titres were similar to the titre against TBEV, confirming the
close antigenic relationship between TBEV and LIV.
However, using these sera, JEV was also antigenically
closer to TBEV than WNV, whilst WNV was in close
proximity to DENV-2. Error lines are shown for each virus
and serum. The length of the error lines is proportional to
the difference between the distance on the figure and the
target distance, and the colour indicates the direction of the
difference (blue5positive difference, i.e. the distance on
the figure is more than the target distance; red5negative).
The error lines are short, indicating that the errors
associated with the positions of the points were small.
MVEV does not appear on the map, as serum cross-
neutralization was not sufficiently robust to position the
virus relative to the others analysed.
DISCUSSION
Both innate and adaptive immune responses are necessary
in order to control flavivirus infection, with the initiation
of an early antibody response providing a critical element
of virus control (Diamond et al., 2003a, b). The flavivirus
envelope glycoprotein is the principal antigen responsible
for eliciting a neutralizing antibody response, although
antibodies specific for the prM and NS1 proteins have also
been detected (Pincus et al., 1992; Colombage et al., 1998;
Shu et al., 2000; Chung et al., 2007). Indeed, the resistance
of WNV to antibody-mediated neutralization has been
directly correlated with mutations in the epitopes of
envelope protein domain III (ED3) (Maillard et al.,
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Fig. 2. Effect of vaccination against YFV on WNV and DENV-2
PRNT50 titre: percentage of samples per vaccination group
(TBEV+JEV vaccination n514; TBEV+JEV+YFV vaccination
n511) achieving either a neutralizing antibody titre of at least 1:10
by PRNT50, or no neutralization (Neg), against WNV or DENV-2.
Samples with uncertain YFV were excluded from the analysis.
Statistical significance between the two vaccination groups was
calculated by Kruskall–Wallis test (P50.002), and is denoted by *.
Table 1. Summary of PRNT results for sera that demonstrated neutralization of WNV
ND, Not determined.
YFV vaccination Neutralizing antibody titre (PRNT50)
YFV (17D) YFV (Asibi) TBEV JEV LIV DENV-2 WNV MVEV
No Neg Neg 1:40 1:160 1:10 Neg 1:20 Neg
Yes Neg Neg Neg 1:40 Neg Neg 1:10 Neg
Yes 1:40 1:80 1:20 1:40 1:10 1:20 1:40 Neg
Yes 1:80 1:80 Neg 1:10 Neg 1:20 1:10 Neg
Yes 1:20 1:20 Neg 1:160 Neg 1:20 1:160 Neg
Yes 1:40 1:80 1:160 1:80 1:40 1:80 1:80 Neg
Yes 1:80 1:160 ND 1:160 1:10 1:20 1:80 Neg
Unknown ND ND ND 1:80 Neg ND 1:10 Neg
Unknown Neg 1:40 1:1280 1:160 1:1280 1:40 1:40 Neg
K. L. Mansfield and others
2824 Journal of General Virology 922008), and a potential role for ED3 in cross-protection
among flaviviruses has been suggested following studies in
mice (Li et al., 2011).
Antibody-mediated immunity is therefore considered a
major modality of protection against members of the
flavivirus serocomplex and is a useful and measurable
correlate of vaccine-induced immunity (Vaughan et al.,
2010). However, there are clearly contradictions and para-
doxes in our current understanding of flavivirus antigenic
relationships that have direct consequences for predicting
protection and for serodiagnosis. Antigenic cartography has
been applied to other pathogens, allowing high resolution
quantitative analyses and visualizations of antigenic rela-
tionships, using sera represented as a single point thus
allowing robust and repeatable maps to be made (Smith et
al., 2004; de Jong et al., 2007; Russell et al., 2008; Huang et
al., 2009; Garten et al., 2009; Horton et al., 2010). The
analysed sera were from volunteers vaccinated with multiple
pathogens, whereas previous applications of antigenic
cartography have used sera produced using either infection
or vaccination with a single pathogen. An assumption in
current antigenic cartography methods is that the position
of the sera on the maps can be represented by a single point.
However, this assumption will only hold if the polyclonal
sera (which will typically include populations of antibodies
which bind to different antigenic components of the virus,
and with differing affinities) can be represented as one
‘centre of action’. In previous studies, this assumption holds
to the first order for sera that have been raised to a single
antigen (Smith et al., 2004; de Jong et al., 2007; Russell et al.,
2008; Huang et al., 2009; Horton et al., 2010). The single
point assumption would not be expected to hold for multi-
infection sera, as the sera will contain an even more diverse
population of antibodies than single-infection polyclonal
sera, and the assumption of sera being adequately repre-
sented by a single point is even less likely to be satisfied.
Despite the nature of the sera in the current study, the error
associated with the position of the sera on Fig. 3 is small, the
maps are robust and repeatable, and this geometric
interpretation of the data is reliable. An important caveat
when interpreting these data is that it does not necessarily
reflect the true antigenic distances among these viruses;
instead it represents how these particular sera relate to the
antigens. For example, given sufficient sera from individuals
vaccinated using a combined measles, mumps and rubella
vaccine (M-M-R), it may be possible to make a geome-
tric interpretation of the relationships between the sera.
YFV 17D
YFV Asibi
WNV
DENV-2
JEV TBEV
LIV
Fig. 3. Geometric illustration of selected
serum neutralization titres against TBEV, LIV,
JEV, WNV, YFV (two strains) and DENV-2
made using antigenic cartography techniques.
Sera are represented by white squares, and
viruses are represented by green circles.
Coloured error lines are shown for each virus
and serum. The length of the error line is
proportional to the difference between dis-
tance on the figure and the target distance; the
colour indicates the direction of the difference
(blue5positive difference, i.e. the distance on
the figure is more than the target distance;
red5negative).
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rubella viruses are antigenically related. Future analyses
using different sera would be expected to show different
relationships. A thorough quantitative analysis of antigenic
variation among and within flavivirus serocomplexes using
single-infection sera is required, in order to better
understand the complex antigenic relationships among the
flaviviruses.
One advantage of antigenic cartography is that it is
minimally dependent on individual variations in sero-
logical response compared with other interpretations of
antigenic data. The cross-reactivities of the sera to the
viruses in the study, and the relationships of the sera to
each other, can be reliably interpreted from Fig. 3. In these
volunteers, vaccination against JEV has failed to produce
sufficient broad cross-neutralization either within the JEV
serocomplex to generate high titres against WNV, nor
against DENV-2 which is in a different serocomplex. Hence
WNV and DENV-2 are much more antigenically distant
from JEV than TBEV is from JEV. However, we cannot
exclude the possibility that formalin inactivation of the
killed JEV vaccine denatured epitopes that cross-react with
WNV. Furthermore, the proximity of JEV to TBEV, and
WNV to DENV-2 would not be expected considering their
genetic relationships, but is likely to be related to these sera
coming from volunteers vaccinated with both TBEV and
JEV. Antigenic relationships measured using sera raised
against alternative viruses are likely to be different. We can
also draw conclusions regarding the positions of the sera.
Despite having similar vaccination regimes, sera differ
greatly in the breadth and focus of response. This is
apparent from the raw titres, but is easily visualized in Fig. 3
where the sera are well distributed, with the response
of some individuals biased towards the TBEV serocomplex
and the response of others biased towards the YFV
serocomplex.
We have demonstrated that human vaccination against
TBEV and JEV elicited a limited antibody response capable
of neutralizing lineage 1 WNV, which is the predominant
lineage circulating in Europe. Although this study did not
control for some variables such as the age of the subjects, or
the time between YFV vaccination and blood sampling, the
results suggest that additional vaccination against YFV
enhanced the ability to neutralize WNV. This conclusion is
at variance with a previous study that concluded that JEV
vaccination was more effective than YFV vaccination for
neutralization of WNV (Yamshchikov et al., 2005). Our
observation is surprising as YFV and WNV are genetically
distinct and belong to different serocomplex groups, a
feature corroborated by the antigenic cartographical
analysis (Fig. 3). However, current vaccines against YFV
are live-attenuated rather than inactivated, and are likely to
be more immunogenic, stimulating a broader spectrum of
responses and inducing a strong humoral immune
response. Both the TBEV and the JEV vaccines used in
this study were formalin-inactivated preparations.
Most individuals vaccinated against TBEV elicited a
measurable titre to LIV. There is currently no human
vaccine available for LIV but the results presented in this
study suggest that vaccination against TBEV may offer
partial protection against infection with LIV. Indeed, a
TBEV vaccine based upon the European prototype strain
Neudoerfl has recently been shown to induce cross-reactive
antibodies in humans, against both other TBEV subtypes
and more distantly related viruses, such as Omsk hemor-
rhagic fever virus (Orlinger et al., 2011). Conversely,
despite the fact that MVEV is genetically and apparently
antigenically closely related to JEV according to previous
studies (Calisher et al., 1989), we observed no significant
neutralization of MVEV following vaccination with an
inactivated whole-virus JEV vaccine. These data support an
earlier study, where sera from mice vaccinated with a
licensed inactivated JEV vaccine (JE-VAX) demonstrated
negligible neutralization of MVEV (Lobigs et al., 2009).
This study has demonstrated that individuals who had
received vaccinations against TBEV, JEV and YFV were
able to neutralize LIV and to a lesser degree lineage 1 WNV
and DENV-2, but not MVEV. However, the majority of
individuals did not develop neutralizing antibodies against
WNV or DENV-2. These data suggest that this vaccination
regimen cannot be recommended to provide consistent
protective immune responses against WNV or DENV, and
emphasizes the need for development of virus-specific
vaccines for use in high-risk groups of infection or severe
disease. However, these data were obtained using specific
virus strains for PRNT, and the use of alternative virus
strains may lead to some degree of variation in the results.
Furthermore, the presence of neutralizing antibodies
against the virus strains used in this study does not
guarantee protection against alternative strains and cur-
rently circulating viruses.
Utilization and manipulation of the cross-reactive prop-
erties of flaviviruses have the potential to assist the
development of effective broad-spectrum human vaccines
against WNV and other existing and emerging flaviviruses.
ChimeriVax technology has advantageously taken the
cross-reactive properties of flaviviruses one step further
in the development of vaccine candidates (Arroyo et al.,
2004; Lobigs et al., 2009). Ultimately, the development of a
broad-spectrum chimeric vaccine with components tailor-
ed to individual viruses would be of benefit in countries
where a number of different flaviviruses co-circulate.
METHODS
Samples. A cohort of 28 individuals (all of white Caucasian ethnic
origin) was established, with a history of vaccination against
flaviviruses. This was primarily based on occupational vaccination
for TBEV (TicoVac, Baxter) and JEV [Japanese Encephalitis (JE)
Vaccine; GCC, Green Cross Corporation]. Blood samples were taken
on completion of the full course of JEV vaccination (which comprises
three doses on days 0, 7 and 28), and after the second vaccination in
the course of TBEV vaccination (which is given 1–3 months after the
K. L. Mansfield and others
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vaccination and blood sampling was 22.5 days (SEM 10.3 days) and
75.2 days (SEM 32.4 days) for TBEV and JEV vaccinations, respect-
ively. There was one individual within the sample population who
had previously completed the full course of three vaccinations against
TBEV, and had also received two booster vaccinations. Similarly, they
had received a JEV booster nearly 2 years after completing the initial
course of vaccinations. The time between last vaccination and blood
sampling for this individual was 20 months and 22 months for TBEV
and JEV vaccinations, respectively. Furthermore, within the cohort
were 11 individuals who had previously received vaccination for YFV
(manufacturer not recorded), and the mean number of years between
vaccination and blood sampling was 9.2 years (SEM 5.1 years). Sera
were separated from whole blood samples and heat inactivated at
56 uC for 30 min.
Viruses. The viruses selected for use in PRNT included lineage 1
WNV, European TBEV, LIV, JEV and MVEV, YFV (two strains) and
DENV-2. Specific details on the origin of each virus are provided in
Supplementary Table S2 (available in JGV Online).
PRNT. PRNT was used to determine cross-neutralization against
WNV, LIV, MVEV or DENV-2, and to demonstrate seroconversion
following vaccination against TBEV, JEV or YFV (Office Internationale
des Epizooties (OIE), 2008). Briefly, a twofold dilution series of serum
was incubated with an equal volume of virus for 30–60 min at 37 uC/
5%CO 2. Serum dilutions were incubated with Vero C1008 cells for
30–60 min at 37 uC/5% CO2 along with wells set up with virus-only
and media-only controls. Following overlay, plates were incubated at
37 uC/5% CO2 for 2 (MVEV), 3 (WNV), 4 (YFV and DENV-2), 5
(JEV) or 6 days (TBEV/LIV). Following fixation and staining, plaques
were counted in each well, and titre calculated according to the
percentage reduction in plaques in comparison with the virus control
wells (PRNT50: .50% reduction in plaque numbers). Serum samples
giving titres ¢1:10 were considered positive.
Visualization of neutralization data using antigenic carto-
graphy techniques. Using techniques described previously (Smith
et al., 2004; Horton et al., 2010) we illustrated the relationships of
TBEV, LIV, JEV, WNV, YFV (two strains) and DENV-2 according to
the titres of selected sera (n517) that neutralized at least three
viruses (,10 is equivalent to negative). Briefly, this first required
deriving a target distance from each serum to each of the seven
viruses. This was done by taking the logarithm2 of all the reciprocal
titres, then calculating the difference between the titre against one
particular virus and the maximum titre achieved by that serum
(against any virus) or 1280, whichever was higher. Neutralization
titres (expressed as ED505reciprocal 50% end point dilutions) and
target distances used for Fig. 3 are shown in Supplementary Table S3
(available in JGV Online). Thus, the target distance between a serum
and virus depends upon the titre against that virus. The target
distance is relative to a fixed higher titre and therefore the higher the
titre of the serum against a virus, the shorter the target distance
between that serum and virus. Antigenic cartography (Smith et al.,
2004) was then used to optimize the positions of the viruses and sera
relative to each other such that the distance between sera and viruses
on the illustration was as close as possible to the target distance
(minimizing the sum-squared error between the distance on the
illustration and the target distance). Each virus is therefore
positioned by multiple sera, and the sera themselves are also
positioned by their distances to the viruses. To increase the
likelihood of obtaining the best match to the target distances,
multiple random restart optimizations (100) were undertaken as in
previous analyses, creating multiple maps that were ranked in order
of total error and quantitatively compared for self-consistency. As in
antigenic maps, the distances between sera and viruses are not
limited to the conventional three dimensions normally visualized.
However, the visualization of these data fits well in two dimensions.
Statistical analysis. Statistical analysis was undertaken using
Spearman’s rank correlation coefficient, Fisher’s exact test,
Kruskall–Wallis test and Student’s t-test (significant, P,0.05; highly
significant, P,0.001). Exact P values for the Kruskall–Wallis test,
Fisher’s exact test and the Spearman’s rank correlation coefficient
were calculated using StatXact software (StatXact 8 Statistical software
for Exact Non-parametric Inference; Cytel Software Corporation).
Ethical review of human work. This manuscript has been approved
for publication by the Veterinary Laboratories Agency Ethics
Committee, and the participants gave their signed consent to the
work.
ACKNOWLEDGEMENTS
We wish to thank Paul Phipps (AHVLA) for technical assistance
with WNV PRNT and Robin Sayers (AHVLA) for statistical analysis.
The WNV isolate was provided by Professor Ernie Gould, Centre for
Ecology and Hydrology, Oxford, UK. TBEV and LIV isolates were
provided by Dr John Stephenson, Health Protection Agency (HPA),
UK. The JEV isolate was provided by the University of Texas Medical
Branch (UTMB), Galveston, USA. The MVEV isolate was provided
by the Special Pathogens Reference Unit (SPRU), HPA, UK. This
study was partially funded by the Department for Environment,
Food and Rural Affairs (Defra) projects SE4106, SEO530 and
Seedcorn project SCO213, and by EU FP7 co-ordinating action
‘ArboZooNet’ International Network for Capacity Building for the
Control of Emerging Viral Vector Borne Zoonotic Diseases (grant
no. 211757).
REFERENCES
Arroyo, J., Miller, C., Catalan, J., Myers, G. A., Ratterree, M. S., Trent,
D. W. & Monath, T. P. (2004). ChimeriVax-West Nile virus live-
attenuated vaccine: preclinical evaluation of safety, immunogenicity,
and efficacy. J Virol 78, 12497–12507.
Autorino, G. L., Battisti, A., Deubel, V., Ferrari, G., Forletta, R.,
Giovannini, A., Lelli, R., Murri, S. & Scicluna, M. T. (2002). West Nile
virus epidemic in horses, Tuscany region, Italy. Emerg Infect Dis 8,
1372–1378.
Bakonyi, T., Ivanics, E ´., Erde ´lyi, K., Ursu, K., Ferenczi, E.,
Weissenbo ¨ck, H. & Nowotny, N. (2006). Lineage 1 and 2 strains of
encephalitic West Nile virus, central Europe. Emerg Infect Dis 12, 618–
623.
Beasley, D. W. C. & Barrett, A. D. T. (2002). Identification of
neutralizing epitopes within structural domain III of the West Nile
virus envelope protein. J Virol 76, 13097–13100.
Bosco-Lauth, A., Mason, G. & Bowen, R. (2011). Pathogenesis of
Japanese encephalitis virus infection in a golden hamster model and
evaluation of flavivirus cross-protective immunity. Am J Trop Med
Hyg 84, 727–732.
Calisher, C. H., Karabatsos, N., Dalrymple, J. M., Shope, R. E.,
Porterfield, J. S., Westaway, E. G. & Brandt, W. E. (1989). Antigenic
relationships between flaviviruses as determined by cross-neutraliza-
tion tests with polyclonal antisera. J Gen Virol 70, 37–43.
Chung, K. M., Thompson, B. S., Fremont, D. H. & Diamond, M. S.
(2007). Antibody recognition of cell surface-associated NS1 triggers
Fc-gamma receptor-mediated phagocytosis and clearance of West
Nile virus-infected cells. J Virol 81, 9551–9555.
Antibody cross-reactivity between flaviviruses
http://vir.sgmjournals.org 2827Colombage, G., Hall, R., Pavy, M. & Lobigs, M. (1998). DNA-based
and alphavirus-vectored immunisation with prM and E proteins
elicits long-lived and protective immunity against the flavivirus,
Murray Valley encephalitis virus. Virology 250, 151–163.
de Jong, J. C., Smith, D. J., Lapedes, A. S., Donatelli, I., Campitelli, L.,
Barigazzi, G., Van Reeth, K., Jones, T. C., Rimmelzwaan, G. F. &
other authors (2007). Antigenic and genetic evolution of swine
influenza A (H3N2) viruses in Europe. J Virol 81, 4315–4322.
Diamond, M. S., Shrestha, B., Marri, A., Mahan, D. & Engle, M.
(2003a). B cells and antibody play critical roles in the immediate
defense of disseminated infection by West Nile encephalitis virus.
J Virol 77, 2578–2586.
Diamond, M. S., Sitati, E. M., Friend, L. D., Higgs, S., Shrestha, B. &
Engle, M. (2003b). A critical role for induced IgM in the protection
against West Nile virus infection. J Exp Med 198, 1853–1862.
Garten, R. J., Davis, C. T., Russell, C. A., Shu, B., Lindstrom, S.,
Balish, A., Sessions, W. M., Xu, X., Skepner, E. & other authors
(2009). Antigenic and genetic characteristics of swine-origin 2009
A(H1N1) influenza viruses circulating in humans. Science 325, 197–
201.
Gaunt, M. W., Sall, A. A., de Lamballerie, X., Falconar, A. K. I.,
Dzhivanian, T. I. & Gould, E. A. (2001). Phylogenetic relationships of
flaviviruses correlate with their epidemiology, disease association and
biogeography. J Gen Virol 82, 1867–1876.
Grard, G., Moureau, G., Charrel, R. N., Lemasson, J. J., Gonzalez,
J. P., Gallian, P., Gritsun, T. S., Holmes, E. C., Gould, E. A. & de
Lamballerie, X. (2007). Genetic characterization of tick-borne
flaviviruses: new insights into evolution, pathogenetic determinants
and taxonomy. Virology 361, 80–92.
Heinz, F.-X., Berger, R., Tuma, W. & Kunz, C. (1983). A topological
and functional model of epitopes on the structural glycoprotein of
tick-borne encephalitis virus defined by monoclonal antibodies.
Virology 126, 525–537.
Hirota, J., Nishi, H., Matsuda, H., Tsunemitsu, H. & Shimiz, S. (2010).
Cross-reactivity of Japanese encephalitis virus-vaccinated horse sera
in serodiagnosis of West Nile virus. J Vet Med Sci 72, 369–372.
Horton, D. L., McElhinney, L. M., Marston, D. A., Wood, J. L. N.,
Russell, C. A., Lewis, N., Kuzmin, I. V., Fouchier, R. A. M., Osterhaus,
A. D. M. E. & other authors (2010). Quantifying antigenic relation-
ships among the lyssaviruses. J Virol 84, 11841–11848.
Huang, S. W., Hsu, Y. W., Smith, D. J., Kiang, D., Tsai, H. P., Lin, K. H.,
Wang, S. M., Liu, C. C., Su, I. J. & Wang, J. R. (2009). Reemergence of
enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic
evolution from 1998 to 2008. J Clin Microbiol 47, 3653–3662.
Huba ´lek, Z., Halouzka, J. & Juricova ´, Z. (1999). West Nile fever in
Czechland. Emerg Infect Dis 5, 594–595.
Kimura-Kuroda, J. & Yasui, K. (1986). Antigenic comparison of
envelope protein E between Japanese encephalitis virus and some
other flaviviruses using monoclonal antibodies. J Gen Virol 67, 2663–
2672.
Kramer, L. D., Styer, L. M. & Ebel, G. D. (2008). A global perspective
on the epidemiology of West Nile virus. Annu Rev Entomol 53, 61–81.
Krisztalovics, K., Ferenczi, E., Molnar, Z., Csohan, A., Ban, E., Zoldi,
V. & Kaszas, K. (2008). West Nile virus infections in Hungary,
August–September 2008. Euro Surveill 13, pii519030. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/19000572
Li, S. H., Li, X. F., Zhao, H., Jiang, T., Deng, Y. Q., Yu, X. D., Zhu, Q. Y.,
Qin, E. D. & Qin, C. F. (2011). Cross protection against lethal West
Nile virus challenge in mice immunized with recombinant E protein
domain III of Japanese encephalitis virus. Immunol Lett 138, 156–160.
Lobigs, M., Larena, M., Alsharifi, M., Lee, E. & Pavy, M. (2009). Live
chimeric and inactivated Japanese encephalitis virus vaccines differ in
their cross-protective values against Murray Valley encephalitis virus.
J Virol 83, 2436–2445.
Maillard, R. A., Jordan, M., Beasley, D. W. C., Barrett, A. D. T. & Lee,
J. C. (2008). Long range communication in the envelope protein
domain III and its effect on the resistance of West Nile virus to
antibody-mediated neutralization. J Biol Chem 283, 613–622.
Murgue,B.,Murri,S.,Zientara,S.,Durand,B.,Durand,J.-P.&Zeller,H.
(2001). West Nile outbreak in horses in southern France, 2000: the
return after 35 years. Emerg Infect Dis 7, 692–696.
Nash, D., Mostashari, F., Fine, A., Miller, J., O’Leary, D., Murray, K.,
Huang, A., Rosenberg, A., Greenberg, A. & other authors (2001).
The outbreak of West Nile virus infection in the New York City area
in 1999. N Engl J Med 344, 1807–1814.
Office Internationale des Epizooties (OIE) (2008). OIE Manual of
Diagnostic Tests and Vaccines for Terrestrial Animals, 6th edn. Paris,
France: Office Internationale des Epizooties.
Orlinger, K. K., Hofmeister, Y., Fritz, R., Holzer, G. W., Falkner, F. G.,
Unger, B., Loew-Baselli, A., Poellabauer, E.-M., Ehrlich, H. J. & other
authors (2011). A tick-borne encephalitis virus vaccine based on the
European prototype strain induces broadly reactive cross-neutralizing
antibodies in humans. J Infect Dis 203, 1556–1564.
Papa, A., Danis, K., Baka, A., Bakas, A., Dougas, G., Lytras, T.,
Theocharopoulos, G., Chrysagis, D., Vassiliadou, E. & other authors
(2010). Ongoing outbreak of West Nile virus infections in humans
in Greece, July–August 2010. Euro Surveill 15, pii519644. http://
www.ncbi.nlm.nih.gov/pubmed/20807489
Peiris, J. S. M., Porterfield, J. S. & Roehrig, J. T. (1982). Monoclonal
antibodies against the flavivirus West Nile. J Gen Virol 58, 283–289.
Pincus, S., Mason, P. W., Konishi, E., Fonseca, B. A., Shope, R. E.,
Rice, C. M. & Paoletti, E. (1992). Recombinant vaccinia virus
producing the prM and E proteins of yellow fever virus protects
mice from lethal yellow fever encephalitis. Virology 187, 290–297.
Porterfield, J. S. (1980). Antigenic characteristics and classification of
Togaviridae.InTheTogaviruses, pp.13–46.EditedbyR.W.Schlesinger.
New York: Academic Press.
Rizzo, C., Vescio, F., Declich, S., Finarelli, A. C., Macini, P., Mattivi, A.,
Rossini, G., Piovesan, C., Barzon, L. & other authors (2009). West
Nile virus transmission with human cases in Italy, August–September
2009. Euro Surveill 14, pii519353. http://www.eurosurveillance.org/
images/dynamic/EE/V14N40/art19353.pdf
Russell, C. A., Jones, T. C., Barr, I. G., Cox, N. J., Garten, R. J.,
Gregory, V., Gust, I. D., Hampson, A. W., Hay, A. J. & other authors
(2008). The global circulation of seasonal influenza A (H3N2) viruses.
Science 320, 340–346.
Schlesinger, J. J. & Brandriss, M. W. (1983). 17D yellow fever virus
infection of P388D1 cells mediated by monoclonal antibodies:
properties of the macrophage Fc receptor. J Gen Virol 64, 1255–
1262.
Schuller, E., Klade, C. S., Heinz, F. X., Kollaritsch, H., Rendi-Wagner,
P., Jilma, B. & Tauber, E. (2008). Effect of pre-existing anti-tick-borne
encephalitis virus immunity on neutralising antibody response to the
Vero cell-derived, inactivated Japanese encephalitis virus vaccine
candidate IC51. Vaccine 26, 6151–6156.
Shu, P. Y., Chen, L. K., Chang, S. F., Yueh, Y. Y., Chow, L., Chien, L. J.,
Chin, C., Lin, T. H. & Huang, J. H. (2000). Dengue NS1-specific
antibody responses: isotype distribution and serotyping in patients
with Dengue fever and Dengue hemorrhagic fever. J Med Virol 62,
224–232.
Smith, D. J., Lapedes, A. S., de Jong, J. C., Bestebroer, T. M.,
Rimmelzwaan, G. F., Osterhaus, A. D. & Fouchier, R. A. (2004).
Mapping the antigenic and genetic evolution of influenza virus.
Science 305, 371–376.
K. L. Mansfield and others
2828 Journal of General Virology 92Takegami, T., Miyamoto, H., Nakamura, H. & Yasui, K. (1982).
Biological activities of the structural proteins of Japanese encephalitis
virus. Acta Virol 26, 312–320.
Tesh, R. B., Travassos da Rosa, A. P. A., Guzman, H., Araujo, T. P. &
Xiao, S.-Y. (2002). Immunization with heterologous flaviviruses
protective against fatal West Nile encephalitis. Emerg Infect Dis 8,
245–251.
Thomas, S. J. & Endy, T. P. (2011). Vaccines for the prevention of
dengue: development update. Hum Vaccine 7, 674–684.
Vaughan, K., Greenbaum, J., Blythe, M., Peters, B. & Sette, A. (2010).
Meta-analysis of all immune epitope data in the Flavivirus genus:
inventory of current immune epitope data status in the context of
virus immunity and immunopathology. Viral Immunol 23, 259–284.
Yamshchikov, G., Borisevich, V., Kwok, C. W., Nistler, R., Kohlmeier, J.,
Seregin, A., Chaporgina, E., Benedict, S. & Yamshchikov, V.
(2005). The suitability of yellow fever and Japanese encephalitis
vaccines for immunization against West Nile virus. Vaccine 23, 4785–
4792.
Antibody cross-reactivity between flaviviruses
http://vir.sgmjournals.org 2829